Publications

Data from Photoacoustic Tomography Detects Response and Resistance to Bevacizumab in Breast Cancer Mouse Models

Authors: I Quiros-Gonzalez, MR Tomaszewski, MA Golinska, E Brown, L Ansel-Bollepalli...

Research group: Bohndiek Group

E-pub date: 31 Mar 2023

Journal name:

Data from Spectral Endoscopy Enhances Contrast for Neoplasia in Surveillance of Barrett’s Esophagus

Authors: DJ Waterhouse, W Januszewicz, S Ali, RC Fitzgerald, M di Pietro, SE Bohndie...

Research group: Bohndiek Group

E-pub date: 31 Mar 2023

Journal name:

Supplementary Data from Spectral Endoscopy Enhances Contrast for Neoplasia in Surveillance of Barrett’s Esophagus

Authors: DJ Waterhouse, W Januszewicz, S Ali, RC Fitzgerald, M di Pietro, SE Bohndie...

Research group: Bohndiek Group

E-pub date: 31 Mar 2023

Journal name:

Supplementary Data from Spectral Endoscopy Enhances Contrast for Neoplasia in Surveillance of Barrett’s Esophagus

Authors: DJ Waterhouse, W Januszewicz, S Ali, RC Fitzgerald, M di Pietro, SE Bohndie...

Research group: Bohndiek Group

E-pub date: 31 Mar 2023

Journal name:

Data from Spectral Endoscopy Enhances Contrast for Neoplasia in Surveillance of Barrett’s Esophagus

Authors: DJ Waterhouse, W Januszewicz, S Ali, RC Fitzgerald, M di Pietro, SE Bohndie...

Research group: Bohndiek Group

E-pub date: 31 Mar 2023

Journal name:

Fate-mapping lymphocyte clones and their progenies from induced antigen-signals identifies temporospatial behaviours of T cells mediating tolerance

Authors: M Takahashi, TY So, K Williamson, Z Hosseini, K Kania, M Ruhle, T Mann, MJ ...

Research group: Halim Group

E-pub date: 21 Mar 2023

Journal name:

From a genome-wide screen of RNAi molecules against SARS-CoV-2 to a validated broad-spectrum and potent prophylaxis.

Authors: O Yogev, O Weissbrod, G Battistoni, D Bressan, A Naamati, I Falciatori, AC ...

Research group: Hannon Group

E-pub date: 16 Mar 2023

Journal name: Commun Biol

CRISPR-Cas9 genetic screen leads to the discovery of L-Moses, a KAT2B inhibitor that attenuates Tunicamycin-mediated neuronal cell death.

Authors: S Pavlou, S Foskolou, N Patikas, SF Field, EK Papachristou, CD Santos, AR E...

Research group: Proteomics

E-pub date: 9 Mar 2023

Journal name: Sci Rep

Filters

Research Groups

Core Facilities

Start date

End date

Data from Photoacoustic Tomography Detects Response and Resistance to Bevacizumab in Breast Cancer Mouse Models

Data from Spectral Endoscopy Enhances Contrast for Neoplasia in Surveillance of Barrett’s Esophagus

Supplementary Data from Spectral Endoscopy Enhances Contrast for Neoplasia in Surveillance of Barrett’s Esophagus

Supplementary Data from Spectral Endoscopy Enhances Contrast for Neoplasia in Surveillance of Barrett’s Esophagus

Data from Spectral Endoscopy Enhances Contrast for Neoplasia in Surveillance of Barrett’s Esophagus

Fate-mapping lymphocyte clones and their progenies from induced antigen-signals identifies temporospatial behaviours of T cells mediating tolerance

From a genome-wide screen of RNAi molecules against SARS-CoV-2 to a validated broad-spectrum and potent prophylaxis.

CRISPR-Cas9 genetic screen leads to the discovery of L-Moses, a KAT2B inhibitor that attenuates Tunicamycin-mediated neuronal cell death.

Themes

Filters

Research Groups

Core Facilities

Start date

End date

Data from Photoacoustic Tomography Detects Response and Resistance to Bevacizumab in Breast Cancer Mouse Models

Data from Spectral Endoscopy Enhances Contrast for Neoplasia in Surveillance of Barrett’s Esophagus

Supplementary Data from Spectral Endoscopy Enhances Contrast for Neoplasia in Surveillance of Barrett’s Esophagus

Supplementary Data from Spectral Endoscopy Enhances Contrast for Neoplasia in Surveillance of Barrett’s Esophagus

Data from Spectral Endoscopy Enhances Contrast for Neoplasia in Surveillance of Barrett’s Esophagus

Fate-mapping lymphocyte clones and their progenies from induced antigen-signals identifies temporospatial behaviours of T cells mediating tolerance

From a genome-wide screen of RNAi molecules against SARS-CoV-2 to a validated broad-spectrum and potent prophylaxis.

CRISPR-Cas9 genetic screen leads to the discovery of L-Moses, a KAT2B inhibitor that attenuates Tunicamycin-mediated neuronal cell death.